Preliminary Data Presented at the 14th International Congress on Infectious Diseases (ICID)
|
|
(HealthNewsDigest.com) – Menveo® (Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine), a quadrivalent meningococcal conjugate vaccine from Novartis Vaccines, was recently approved in the US and EU to prevent meningococcal disease in adolescents and adults. The vaccine is now available in doctors’ offices throughout the US.
Since the approval of Menveo, preliminary data, which evaluated antibody persistence, was presented. Antibody persistence after vaccination is one of the key attributes expected of meningococcal conjugate vaccines. According to the study:
Menveo induced at least equivalent or higher immune responses than those induced by Menactra® (sanofi pasteur), the other currently licensed meningococcal conjugate vaccine, in adolescents and adults one-month post-vaccination
A majority of adolescents maintained bactericidal antibody titers ≥1:8 against meningococcal serogroups C, W and Y approximately two years after receiving a single dose of meningococcal conjugate vaccine
For serogroups A, W-135 and Y, a significantly higher proportion of subjects who had been vaccinated with Menveo had hSBA titers at or exceeding 1:8 compared with subjects who received the licensed comparator conjugate meningococcal vaccine
Additionally, for serogroups A and Y GMTs were significantly higher among Menveo recipients
The higher persistence rates demonstrated in the study may be explained by higher GMTs resulting from the primary response to each vaccine.
These study findings are of significant importance because the clinical progression of meningococcal disease may be so rapid that individuals whose antibody titers are below a protective threshold may be susceptible to invasive disease.
Meningococcal disease is a leading cause of bacterial meningitis – an infection of the membrane around the brain and spinal cord – or septicemia – a blood infection. Five serogroups cause the majority of meningococcal disease worldwide: A, B, C, Y and W-135. Epidemiology of meningococcal disease is constantly changing, so it is impossible to determine which serogroups will result in the majority of disease cases year over year.
Meningococcal disease infects more than 500,000 people each year, leading to more than 50,000 deaths globally. In the US, incidence of meningococcal disease varies, ranging between 1,000 and 3,000 cases per year. Even with early and appropriate treatment, as many as one in every seven patients who contract the disease will die from it, often within 24-48 hours of onset of symptoms. Approximately one in five meningococcal disease survivors suffer serious, permanent and devastating side effects, including limb amputations, seizures, paralysis, hearing loss and learning disabilities.
For more information, please visit Novartis Vaccines or www.meningitis.com.
Subscribe to our FREE Ezine and receive current Health News, be eligible for discounted products/services and coupons related to your Health. We publish 24/7.
HealthNewsDigest.com
For advertising or promotion, email: [email protected]